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The real-world use of different anti-tumor necrosis 
factor agents in a Northern European population of 
patients with Behçet’s disease
Introduction
Since the first description of the tri-symptom complex by Professor Hulusi Behçet 80 years ago, there have 
been major developments in the understanding of the epidemiology, pathogenesis, diagnosis, and thera-
py in Behçet’s disease (BD) (1). Management of BD requires a long-term multidisciplinary approach and is 
best coordinated by a specialist team with rheumatologists often having a leadership role (2). The current 
treatment practice for BD focuses on symptomatic treatment, including the prevention of irreversible or-
gan damage and death, suppression of mucocutaneous or joint manifestations, and improvement of the 
patients’ quality of life.
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Abstract
Objective: The aim of this study was to evaluate prescription practices, treatment responses, 
and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet’s disease 
(BD).
Material and Methods: Patients with BD satisfying the International Study Group for Behçet’s Disease 
or the International Criteria for Behçet’s Disease criteria were recruited from a regional rheumatology 
program. The choice of anti-TNF, treatment response, and adverse events were specified. Response 
to treatment was evaluated by the detection of new, worsening, or improving clinical features, and 
management was benchmarked against current The European League against Rheumatism recom-
mendations published in 2008.
Results: Out of the total of 22 patients, 18 (81.9%) received anti-TNF therapies, resulting in 14 (77.8%) 
complete and 4 (22.2%) partial remissions. Eleven (61.1%) patients switched to a second anti-TNF, 
seven patients (38.9%) required three different anti-TNFs, and one required a fourth anti-TNF to 
achieve remission. Two patients required retrials before their disease was controlled. Anti-TNF ther-
apy included infliximab (IFX): n=15, 83.3%; adalimumab (ADA): n=9, 50%; golimumab: n=6, 33.3%; 
etanercept: n=5, 27.8%; and certolizumab pegol: n=2, 11.1%. Secondary failure was observed with 
IFX (4/15; 26.7%) and ADA (2/9; 22.2%), and these (100%) were manifested after at least 2 years of 
treatment. Five patients with potentially life-threatening laryngeal involvement received anti-TNFs 
successfully halting disease progression. Five allergic reactions were encountered, and five serious 
infections were documented involving three patients aged ≥ 50 years, all with the use of IFX.
Conclusion: Anti-TNF therapy induced a clinical response in 100% patients and achieved complete 
remission in 78% patients. It provides an effective alternative option for first-line therapy in severe BD 
where many conventional immunosuppressive therapies fail. Patients with BD who do not respond 
to one or more anti-TNFs because of intolerance, ineffectiveness, or secondary failure might benefit 
from switching to another drug from this group or even a retrial of a previously administered anti-TNF 
because unsatisfactory results with one biologic is not predictive of response to another anti-TNF. For 
those with potentially life-threatening destructive laryngeal manifestation, anti-TNF as a first choice 
may be considered.
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The main treatment for systemic manifes-
tations in BD is tailored based upon the pat-
tern and severity of symptoms and includes 
corticosteroids together with steroid-sparing 
immune-modulators, such as azathioprine 
or cyclosporine, and more recently biological 
therapies (3-6). Patient selection for biological 
therapy has, in general, been based upon indi-
vidual consultant opinion and several open-la-
bel studies. The European League Against 
Rheumatism (EULAR) Standing Committee for 
Clinical Affairs (ESCCA) initiative, a collabora-
tion of experts from eight different countries, 
agreed on a set of recommendations based 
on the best evidence and expert opinion. 
The final set of recommendations identified 
anti-TNF as an option for patients with severe 
inflammatory eye disease, gastrointestinal in-
volvement, CNS involvement, and in resistant 
cases (6). Emerging data support the use of an-
ti-TNF biologics in BD for potentially sight- or 
life-threatening manifestations due to ocular, 
neurological, or major vascular involvement (5-
8). In one randomized controlled clinical trial, 
etanercept was effective against mucocutane-
ous manifestations of BD (9). However, the risk 
of serious infections, including reactivation of 
tuberculosis, and high cost remain important 
concerns (10-12).
Herein, we present our clinical experience 
with anti-TNF biological therapies for BD in a 
Northern European population. The aim of the 
study was to assess prescription practices and 
treatment response to five different anti-TNF 
disease-modifying agents in rheumatic dis-
ease (DMARD) and to describe adverse event 
profiles.
Material and Methods
A retrospective study was conducted on all pa-
tients with BD who attended the rheumatolo-
gy department at University Hospital Limerick, 
Ireland, up to February 2017. Patients satisfied 
the International Study Group for Behçet’s Dis-
ease (ISGBD) or the International Criteria for 
Behçet’s Disease (ICBD) criteria. Demograph-
ic and clinical characteristics were captured 
on all patients at baseline. Data on symptom 
complex, organ involvement, inflammatory 
markers, and treatment strategy, along with 
response rates and adverse effects, were cap-
tured at follow-up clinic visits and through pa-
tient interviews. 
Patients were trialed up to 16 weeks with an an-
ti-TNF, which included dose optimization/esca-
lation, before switching to a different anti-TNF 
if there was no improvement of clinical signs 
and symptoms with the induction therapy or 
if there were signs and symptoms consistent 
with clinical relapse. Patients were trialed up 
to 24 weeks if there was some but insufficient 
clinical response. All patients were screened for 
latent tuberculosis, which included a history of 
tuberculosis exposure, tuberculin skin test, and 
chest x-ray prior to commencement of an-
ti-TNF biological therapy.
“Complete responders” were defined as pa-
tients who experienced a full disappearance 
at any time of signs and symptoms as previ-
ously described after therapy with or with-
out corticosteroid dose of ≤10 mg/day at 6 
months. “Partial responders” were classified 
as patients with significant improvement in 
signs and symptoms and reduction of >50% 
of the initial corticosteroid dose. All other pa-
tients were considered as non-responders. 
The management strategy was compared to 
current EULAR recommendations published 
in 2008 (4). We determined the frequency 
of serious infections and the time between 
commencement of biological therapies and 
infection onset. Serious infections were de-
fined as infections that required intravenous 
antimicrobials and hospitalization. The study 
was approved by the local ethics committee 
and is in accordance with the Declaration of 
Helsinki. Statistical analyses were performed 
using IBM Statistical Package for Social Scienc-
es Version 22.0 software for Macintosh (IBM 
Corp.; Armonk, NY, USA).
Results
Out of a cohort of 22 Caucasian patients of 
Irish descent (mean age of 42.0 years), 18 
(81.9%) received anti-TNF biologic therapies 
(6 males, 12 females) (Table 1). The indications 
to initiate anti-TNF therapy included ocular 
disease-six patients with uveitis, one resulting 
in permanent blindness (6/18), destructive 
laryngeal disease (5/18), vascular manifesta-
tions-including one pulmonary embolus and 
four deep vein thromboses (3/18), severe mu-
cocutaneous lesions with significant impact 
on the quality of life (15/18), and resistance or 
intolerance to conventional treatments (8/18). 
Some patients had more than one indication 
for anti-TNF therapy initiation.
Anti-TNFs included infliximab (IFX): n=15, 
83.3%; adalimumab (ADA): n=9, 50%; golim-
umab (GOL): n=6, 33.3%; etanercept (ETA): n=5, 
27.8%; and certolizumab pegol (CER): n=2, 
11.1%. Out of the 18 patients, 11 (61.1%) (all of 
whom were on IFX infusion) were switched to 
a second anti-TNF, 7 patients (38.9%) needed at 
least three different anti-TNFs, 1 patient needed 
a fourth anti-TNF, and 2 patients needed retrial 
with IFX before their diseases were controlled 
(Table 2, 3). Currently, all 18 patients have been 
on a stable dose of anti-TNFs for more than 18 
months (Table 3).
All 18 patients on anti-TNF achieved satisfacto-
ry remission; 14 (78%) patients were complete 
responders achieving complete remission, 
and the other 4 (22%) patients were partial re-
sponders. Secondary failure was observed with 
IFX (4/15, 26.7%) and ADA (2/9, 22.2%), and all 
secondary failures were observed after at least 
2 years of treatment. Thus far in our experience, 
ETA has been effective in all five of our patients 
achieving complete remission.
Five patients (27.7%) developed type I hyper-
sensitivity reactions, all of whom were admin-
istered IFX. Three patients (16.7%) presented 
with acute mild flushing, chest discomfort, 
and rash, while two patients (11%) developed 
more severe reactions requiring intravenous 
hydrocortisone and anti-histamine. We iden-
tified five cases of serious infections involving 
three patients (16.7%), all of whom were ad-
ministered IFX and all of whom required in-
travenous antimicrobials and hospitalization. 
These included one case of pneumonia, two 
cases of urosepsis, one case of infective chol-
angitis, and one case of herpes zoster. Only 
one of these patients was on a concomitant 
conventional DMARD in the form of metho-
trexate 15 mg weekly. The lag time between 
infections and initiation of biologic therapy 
was 60, 96, and 96 weeks (the same patient at 
week 96 had two infections, pneumonia and 
herpes zoster) in one patient and 56 and 214 
weeks in the next two patients, respectively. 
All patients had swift recovery and have been 
recommenced biological therapy since then. 
None of our patients developed any other 
severe adverse events such as reactivation 
of tuberculosis, malignancies, demyelinating 
disease, or congestive cardiac failure.
Patients received rapid tapering doses of oral 
steroid therapy or intramuscular steroid depot 
injections for disease flares, and 11 patients 
were maintained on long-term low steroid 
doses (5 mg oral prednisolone or less). Only 
one patient remained on a conventional im-
mune-modulator as a combination therapy in 
the form of methotrexate 15 mg weekly. Pre-
vious unsuccessful immunosuppressant thera-
pies among our patients included azathioprine 
in seven patients; cyclosporine, methotrexate, 
and thalidomide in two patients each; and my-
cophenolate mofetil in one patient (a patient 
may have been on more than one conven-
tional immunosuppressant at different times) 
(Table 3).
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Discussion
Behçet's disease was previously considered to 
be extremely rare (0.64 per 100,000 population) 
in Northern European populations such as Ire-
land and the UK (13). While most physicians in 
this part of the world encounter very few cases 
of BD during their entire career, we current-
ly care for a total of 22 Irish patients with BD 
from the catchment areas of Limerick, North 
Tipperary, and Clare in the Midwest Region of 
Ireland (population 385,172) (14) who attend 
our rheumatology outpatient department on 
a regular basis and whose diagnosis was made 
in line with international diagnostic guidance 
(15) (point prevalence of 5.71:100,000 popula-
tion). The unusually high prevalence in this re-
gion may, in part, be due to improved disease 
recognition and close interactions across mul-
tiple specialties including ophthalmology, oto-
laryngology, maxillofacial surgery, infectious 
disease, dermatology, hematology, gastroen-
terology, and general practitioners.
The pathergy phenomenon is an inappropri-
ate hyperreactivity response to minor trauma 
such as a needle prick. It is more commonly 
observed among BD populations along the 
Silk Route and is detected more frequently in 
patients with HLA-B*51 and active disease (16-
17). Its sensitivity has declined over time yet 
continues to carry significant diagnostic value, 
especially in the highly prevalent countries (16, 
18). The phenomenon is, however, rarely ob-
served within the Northern European popula-
tions (19-21). In our cohort, two patients (9%) 
Table 1. Clinical manifestations of patients with BD and the anti-TNFs used (n=22)
No G Age AOU GU OL CL PP VI GI ENT B1 B2 B3 B4
1 F 25 + + - + - - - + IFX ADA - -
2 M 71 + - + + - - - + IFX GOL ADA -
3 F 35 + + - + - - - + IFX - - -
4 M 53 + + + + + - + + IFX ADA GOL -
5 F 38 + + - + - - - + IFX ETA - -
6 F 24 + + - + - - - + IFX ADA GOL -
7 F 19 + + + + - - - - IFX - - -
8 M 50 + + + + - + - - IFX - - -
9 M 57 + - + + - - - + IFX ADA IFX-r -
10 F 38 + + - + - - - - IFX CER - -
11 F 39 + + - + - - - - IFX ADA GOL -
12 F 39 + + - - + - - - - - - -
13 M 35 + + - + - - - - ETA - - -
14 F 39 + + - + - - - - - - - -
15 F 53 + + - + - + - - IFX ADA GOL IFX-r
16 F 83 + + + + - - - - IFX - - -
17 F 68 + + - + - - + - - - - -
18 M 47 + + - - - + - - ETA - - -
19 F 39 + + - + - - - - - - - -
20 F 24 + + + + - - - - IFX ADA GOL CER
21 F 23 + + - + - - - - IFX ADA ETA -
22 F 25 + + - + - - - - ETA - - -
AOU: recurrent aphthous oral ulcers; GU: genital ulcers; *OL: ocular lesions CL: cutaneous lesions; PP: positive pathergy test; VI: vascular involvement; GI: gastrointestinal involvement; **ENT: otolaryngeal 
manifestations; B: anti-TNF biologics; IFX: infliximab; IFX-r: retrial with infliximab ADA: adalimumab; ETA: etanercept; GOL: golimumab; CER: certolizumab pegol
*OL, this includes six patients with uveitis confirmed by the ophthalmologist and another patient who presented with bilateral painful, red eyes and transient loss of her left lateral vision but had a negative 
slit-lamp exam for uveitis 
**ENT, this includes two patients with nasopharyngeal ulcerations, tonsillar ulcers/hypertrophy, and sensorineural deafness as well as the five patients deemed to have more significant laryngeal destruction
Table 2. Choice of anti-TNF biological therapy for patients with BD in the Midwest Region of 
Ireland
Anti-TNF 1st 2nd 3rd 4th Retrial Secondary Failures
IFX 15 0 0 0 2 4 (all after 2 years)
ADA 0 8 1 0 0 2 (all after 2 years)
ETA 3 1 1 0 0 0
GOL 0 2 4 0 0 0 (but one needed  
      dose increment)
CER 0 1 0 1 0 0
Anti-TNF: anti-tumor necrosis factor alpha; IFX: infliximab; ADA: adalimumab; ETA: etanercept; GOL: golimumab; CER: 
certolizumab pegol
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Table 3. Patients with BD, the conventional immune-modulators and anti-TNFs used (n=22)
No G Age (YFC) Conventional immune-modulators Anti-TNF
1 F 25 (2007) AZA 50 mg BD PO (Sept 07-Sept 09): ineffective 1. IFX 3 mg/kg, 8/52ly (Nov 10-Dec 13): traveling abroad for a  
    prolonged period 
    2. ADA 40 mg SC, 2/52ly (Jan 14-N)
2 M 71 (2006) AZA 75 mg BD PO (Nov 12-Mar 13): ineffective 1. IFX 5 mg/kg, 6/52ly (Mar 11-Mar 13): 
   MTX 15 mg weekly PO (Oct 13-N) secondary failure 2. GOL (Apr 13-Oct 13): ineffective 
    3. ADA 40 mg SC, 2/52ly (Oct 13-N)
3 F 35 (2011) - IFX 5 mg/kg, 6/52ly (July 11-N)
4 M 53 (1999) AZA 75 mg BD PO (Apr 04-Apr 06):ineffective 1. IFX 5 mg/kg (Jan 09): hypersensitivity reaction 
    2. ADA 40 mg SC, 2/52ly (Feb 09-Aug 12): secondary failure 
    3. GOL 50 mg SC 1/12ly (Aug 12-May 15), GOL 100 mg SC 1/12ly  
    (May 15-N) as flares were observed at 50 mg dose
5 F 38 (2010) - 1. IFX 5 mg/kg 6/52ly (Apr 10-Feb 15): secondary failure 
    2. ETA 50 mg SC weekly (Feb 15-N)
6 F 24 (2012) - 1. IFX 5 mg/kg 6/52 (Nov 12): hypersensitivity reaction 
    2. ADA 40 mg SC, 2/52ly (Jan 13-Jun 13): ineffective 
    3. GOL 50 mg SC 1/12ly (July 13-N)
7 F 19 (2010) - IFX 5 mg/kg 6/52ly (June 11-N)
8 M 50 (1984) CysA*: treated for 6 months: ineffective IFX 5 mg/kg, 6/52ly(Dec 08-N) 
   THAL*: ineffective
9 M 57 (2001)  1. IFX 5 mg/kg, 6/52ly (Jan 09): GI upset 
    2. ADA 40 mg SC, 2/52ly (Feb 09-Aug 09): ineffective 
    3. IFX-r (Nov 09-N)
10 F 38 (2009) AZA 50 mg BD PO (Feb 09): skin rash 1. IFX 5 mg/kg, 6/52ly (Oct 09-Dec 11):secondary failure 
   MTX 10 mg weekly PO (Mar 09): GI upset 2. CER 200 mg SC, 2/52ly (Jan 11-N) 
   MMF 1 g BD PO (Apr 09-Oct 09): ineffective 
11 F 39 (2013) AZA 75 mg BD PO (Jan 13-May 13) -ineffective 1. IFX 5 mg/kg, 6/52ly (Jan 13): hypersensitivity reaction 
    2. ADA 40 mg SC, 2/52ly (Feb-May 13): ineffective 
    3. GOL 50 mg SC 1/12ly (June 13-N)
12 F 39 (2014) - -
13 M 35 (2015) - ETA 50 mg SC, 1/52ly (June 15-N)
14 F 39 (1992) - -
15 F 53 (1993) THAL (Jan-Dec 2005): ineffective 1. IFX 5 mg/kg, 6/52ly (Apr 09-Mar 10): partial remission 
   CysA (July 06): GI upset 2. ADA 40 mg SC, 2/52ly (Mar 10-Sep 10): ineffective 
   AZA (Oct 06- Oct 08): ineffective 3. GOL 50 mg SC (Oct 10-Mar 11): ineffective 
   MTX (Feb 09): GI upset 4. IFX-r 5 mg/kg, 6/52ly (Mar 11-N)
16 F 83 (2000) AZA*: ineffective IFX 5 mg/kg, 6/52ly (Mar 09-N)
17 F 68 (2012) - -
18 M 47 (2014) - ETA 50 mg SC 1/52ly (May 14-N)
19 F 39 (2014) - -
20 F 24 (2008) - 1. IFX 3 mg/kg (Mar 09): hypersensitivity reaction 
    2. ADA 40 mg SC, 2/52ly(Sep 09-Nov 11): secondary failure 
    3. GOL 50 mg SC, 1/12ly (Jan 12-Jul 12): ineffective 
    4. CER 200 mg SC, 2/52ly (Feb 13-Sep 13), 
    CER 200 mg SC, 1/52ly (Sept 13-N): as flares were observed at the  
    lower dose
21 F 23 (2006) - 1. IFX 3 mg/kg (Apr 09): hypersensitivity reaction 
    2. ADA 40 mg SC, 2/52 (Jul 09-Oct 09): ineffective 
    3.ETA 50 mg SC, 1/52ly (Nov 09-N)
22 F 25 (2014) - ETA 50 mg SC, 1/52ly (June 15-N)
AOU: recurrent aphthous oral ulcers; GU: genital ulcers; *OL: ocular lesions CL: cutaneous lesions; PP: positive pathergy test; VI: vascular involvement; GI: gastrointestinal involvement; **ENT: 
otolaryngeal manifestations; B: anti-TNF biologics; IFX: infliximab; IFX-r: retrial with infliximab ADA: adalimumab; ETA: etanercept; GOL: golimumab; CER: certolizumab pegol
*OL, this includes six patients with uveitis confirmed by the ophthalmologist and another patient who presented with bilateral painful, red eyes and transient loss of her left lateral vision but had a 
negative slit-lamp exam for uveitis 
**ENT, this includes two patients with nasopharyngeal ulcerations, tonsillar ulcers/hypertrophy, and sensorineural deafness as well as the five patients deemed to have more significant laryngeal 
destruction
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had a positive response to the skin pathergy 
test (assessed 48 hours after intradermal in-
jection to the flexor aspect of their forearm), 
similar to previous studies in this geographical 
region. Of note, only one of our patients was 
HLA-B*51 positive, and the patient did not have 
a positive pathergy reaction (Table 1) (22). We 
recognize, however, the inherent limitations to 
the pathergy testing in our cohort, including 
the small sample size and that the majority of 
patients were in clinical remission when the 
test was performed.
Traditionally, BD was an exceptionally difficult 
disease to treat. While some patients respond-
ed reasonably well to topical treatments for 
mucocutaneous disease, for the majority with 
systemic disease, response to immunomodu-
lation has generally been poor. Consequently, 
many patients received regular high doses of 
corticosteroids for disease flares with resultant 
long-term side effects, and in severe disease 
patients historically required thalidomide treat-
ment, despite its strong toxicity profile and lack 
of license, because it was effective in some of 
the worst patients who did not respond to 
other treatments. In our study, a total of eight 
patients were on conventional immunosup-
pressants prior to commencement of anti-TNF 
and were treated for at least 3 months before 
treatment was deemed ineffective (Table 3). It 
is also noteworthy that none of our patients 
treated with conventional immunosuppres-
sion alone achieved full remission. Three con-
ventional agents on four occasions involv-
ing two patients had to be stopped within a 
month because of intolerance and side effects 
(methotrexate caused severe upper gastro-
intestinal symptoms in two patients, azathi-
oprine was stopped because of a skin rash in 
one patient, and the final patient could not tol-
erate cyclosporine because of gastrointestinal 
side effects).
The advent of biological therapies has changed 
the whole vista regarding the treatment of the 
more common autoimmune diseases such as 
rheumatoid arthritis (RA) in the past decade. 
More recently, biological therapies have been 
tried in many of the less common orphan au-
toimmune diseases such as BD, and in many 
cases the benefits have been dramatic. In our 
10-year experience of using anti-TNF in our 
cohort, we found it to be generally effective 
with an acceptable safety profile and tolera-
bility resulting in a clinical improvement in all 
of our patients. The therapeutic efficacy can 
be maintained for a prolonged period of time; 
however, some patients do develop secondary 
failure with time and may require a switch to a 
different anti-TNF (or other biological therapy) 
to re-instate disease control. It is also impera-
tive for us as clinicians to closely monitor our 
patients and to communicate with them ap-
propriately so as to improve compliance and 
avoid unnecessary adverse events.
Current EULAR recommendations were tai-
lored based on previous data that BD follows 
a more severe course, especially among young 
men (6). However, it is becoming more appar-
ent that the disease follows different pheno-
types depending on its geographical distribu-
tion (23-26). Five of our patients with significant 
laryngeal and nasopharyngeal involvement 
were deemed deserving of anti-TNF treatment. 
One of the central points of a recent study by 
Fitzgerald et al. is that in a Northern European 
population with BD and oropharyngeal ulcer-
ation, significant and potentially life-threat-
ening pharyngeal damage may be occurring 
unbeknown to physicians and may be more 
common than was previously thought (27).
The percentage of patients in our cohort treat-
ed with anti-TNF is high (81.9%) when com-
pared to other countries or other approved 
indications for anti-TNF such as RA (28-30). 
However, other available treatments for BD 
have limited efficacy and/or are more toxic, 
such as thalidomide, cyclosporine, and pro-
longed use of high-dose steroids. In Ireland, 
anti-TNF therapies are available to patients 
deemed suitable by the prescribing physician, 
and we believe that patients with severe po-
tentially organ- and/or life-threatening disease 
such as destructive laryngeal or nasopha-
ryngeal involvement are suitable candidates. 
Moreover, timely treatment with these agents 
is likely to be cost effective in preventing future 
hospitalization and or surgical intervention. 
We also highlight the unusually high disease 
activity in relatively older patients and among 
females. Our findings challenge the notion of 
similar patterns of presentation of BD in North-
ern European populations. We highlight sig-
nificant heterogeneity in organ involvement, 
especially the phenotype of laryngeal and 
nasopharyngeal destruction. These findings 
would suggest substantial geographical and 
genetic variance.
More recently, three new patients in our clinic 
were commenced on ETA as first choice an-
ti-TNF, and all three patients have had excellent 
responses and remain in complete remission. 
IFX and ADA, however, remain the drug of 
choice for patients with uveitis. We have opted 
to use regularly scheduled IFX infusion as the 
main first-line biological therapy option in the 
majority of our patients because of its proven 
dramatic sustained efficacy in previous studies, 
especially for uveitis associated with BD (31-34). 
In comparison to the 2008 EULAR recommen-
dations that suggested IFX be used as a combi-
nation or add-on therapy with azathioprine in 
refractory eye involvement, our patients who 
presented with uveitis were treated early with 
IFX as monotherapy and had favorable out-
comes. This early and aggressive approach was 
also partly because of the unfortunate fact that 
one of our patients (patient 8) became blind 
on one eye after his uveitis was unsuccessfully 
managed with the conventional immunosup-
pressants cyclosporine and thalidomide prior 
to the era of anti-TNF (Table 3).
High clinical response rates were observed ini-
tially with IFX; however, some patients tended 
to experience decreased efficacy over a period 
of time, usually after the 2nd year. Fifteen of our 
patients were commenced on IFX as the first 
choice anti-TNF, but among them five patients 
developed allergic reactions, with two having 
severe reactions and four developing second-
ary failure (all after2 years). One was switched 
to a different subcutaneous anti-TNF because 
they wished to travel abroad for a prolonged 
period, and a total of four patients achieved 
sustained prolonged remission and continued 
to be on treatment. Two patients did have re-
trials with IFX, one who initially developed up-
per gastrointestinal symptoms, which settled, 
and did not develop any further reactions with 
the retrial and has since achieved complete 
remission, and one who managed to maintain 
a low-disease activity, again without further 
reaction.
We found that with anti-TNF biological therapy, 
clinical response was evident in 100% of our 
patients with 78% achieving complete remis-
sion. Anti-TNF was extremely effective in sup-
pressing the mucocutaneous oral and larynge-
al manifestations thus significantly improving 
our patients’ quality of life. However, resistant 
genital ulcers were often a difficult symptom 
to control, with three patients only achieving 
partial remission.
Our study demonstrated that anti-TNF therapy 
provides an effective alternative option for first-
line therapy in severe BD where conventional 
immunosuppressive therapy fails. Patients who 
do not respond to one or more anti-TNFs be-
cause of intolerance, ineffectiveness, or sec-
ondary failure may benefit from switching to 
another drug from this group or even retrial of 
a previously administered anti-TNF because an 
unsatisfactory result with one biologic is not 
predictive of response to another anti-TNF. For 
those with potentially life-threatening destruc-
tive laryngeal manifestation, anti-TNF as a first 
258
Adeeb et al. Different anti-TNF agents in Behçet’s disease Eur J Rheumatol 2017; 4: 254-9
choice may be considered. While we acknowl-
edge the small number of patients as a lim-
itation for this study, we believe nevertheless 
that these patients are a true reflection of the 
BD population because of its low prevalence 
in the Northern European population and that 
this study provides valuable insights to support 
the safety and efficacy of anti-TNF biologics in 
BD, particularly in non-endemic regions.
Ethics Committee Approval: The study was approved 
by the local ethics committee (Research Ethics Com-
mittee & the Risk Management Department, Uni-
versity Hospital Limerick, Limerick, Ireland) and is in 
accordance with the Declaration of Helsinki.
Peer-review: Externally peer-reviewed.
Acknowledgement: We would like to thank Professor 
Ailish Hannigan for her assistance in the statistical 
analysis.
Author Contributions: Concept F.A., W.L.N., M.U.K., 
A.G.S., A.D.F.; Design - F.A., W.L.N., M.U.K., A.G.S., A.D.F.; 
Supervision - F.A., W.L.N., M.U.K., A.G.S., A.D.F.;  Re-
sources - F.A., W.L.N., M.U.K., A.G.S., A.D.F.; Materials 
- F.A., W.L.N., J.D., A.D.F.;  Data Collection and/or Pro-
cessing - F.A., W.L.N. M.U.K.; Analysis and/or Interpre-
tation F.A., W.L.N., A.D.F.; Literature Search F.A., A.D.F.; 
Writing Manuscript - F.A., A.G.S., J.D., A.D.F.; Critical 
Review- F.A., A.G.S., J.D., A.D.F.
Conflict of Interest: No conflict of interest was de-
clared by the authors.
Financial Disclosure: The authors declared that this 
study has received no financial support.
References
1. Behçet H. Über rezidivierende, aphthose, dürch 
ein Virus verursachte Geshwure am Munde, am 
Auge und an den Genitalien. Dermatol Wo-
chenschr 1937; 36: 1152-57.
2. Haskard DO. Behçet’s syndrome. Medicine 
2014; 42: 180-83. [CrossRef ]
3. Saadoun D, Wechsler B, Terrada C, Hajage D, Le 
Thi Huong D, Resche-Rigon M, et al. Azathio-
prine in severe uveitis of Behçet’s disease. Ar-
thritis Care Res 2010; 62: 1733-38. [CrossRef ]
4. Hatemi G, Silman A, Bang D, Bodaghi B, Cham-
berlain AM, Gul A, et al. EULAR recommenda-
tions for the management of Behçet disease. 
Ann Rheum Dis 2008; 67: 1656-62. [CrossRef ]
5. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. An-
ti-TNF agents for Behçet’s disease: analysis of 
published data on 369 patients. Semin Arthritis 
Rheum 2011; 41: 61-70. [CrossRef ]
6. Hatemi G, Silman A, Bang D, Bodaghi B, Cham-
berlain AM, Gul A, et al. Management of Behçet 
disease: a systematic literature review for the 
European League Against Rheumatism evi-
dence-based recommendations for the man-
agement of Behçet disease. Ann Rheum Dis 
2009; 68: 1528-34 [CrossRef ]
7. Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu 
M, Hatemi G, Ozguler Y, et al. Pulmonary artery 
involvement in Behçet's syndrome: Effects of 
anti-Tnf treatment. Semin Arthritis Rheum 2015; 
45: 369-73. [CrossRef ]
8. Desbois AC, Addimanda O, Bertrand A, Deroux 
A, Pérard L, Depaz R, et al. Efficacy of Anti-TNFα 
in Severe and Refractory Neuro-Behcet Disease: 
An Observational Study. Medicine (Baltimore) 
2016; 95: e3550.
9. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus 
F, Yurdakul S, et al. Short-term trial of etanercept 
in Behçet’s disease: a double blind, placebo 
controlled study. J Rheumatol 2005; 32: 98-105.
10. Talarico R, Bazzichi L, d’Ascanio A, Ferrari C, Ele-
fante E, Tani C, et al. Rate of serious infections 
in Behçet’s disease patients receiving biologic 
therapies: a prospective observational study. 
Clin Rheumatol 2013; 32: 1547-48. [CrossRef ]
11. Van Dartel SA, Fransen J, Kievit W, Flendrie M, 
den Broeder AA, Visser H, et al. Difference in the 
risk of serious infections in patients with rheu-
matoid arthritis treated with adalimumab, in-
fliximab and etanercept: results from the Dutch 
Rheumatoid Arthritis Monitoring (DREAM) regis-
try. Ann Rheum Dis 2013; 72: 895-900. [CrossRef ]
12. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, 
Nagasawa H, et al. Time-dependent increased 
risk for serious infection from continuous use 
of tumor necrosis factor antagonists over three 
years in patients with rheumatoid arthritis. Ar-
thritis Care Res 2012; 64: 1125-34.
13. Chamberlain MA. Behcet’s syndrome in 32 pa-
tients in Yorkshire. Ann Rheum Dis 1977; 36: 
491-99. [CrossRef ]
14. Preliminary report of the 2016 census, Central 
Statistics Office, Dublin, Republic of Ireland.
15. International study group for Behçet’s disease. 
Criteria for diagnosis of Behçet’s disease. Lancet 
1990; 335: 1078-80.
16. Davatchi F, Shahram F, Chams-Davatchi C, 
Shams H, Nadji A, Akhlaghi M, et al. Behçet’s dis-
ease: from east to west. Clin Rheumatol 2010; 
29: 823-33. [CrossRef ]
17. Varol A, Seifert O, Anderson CD. The skin path-
ergy test: innately useful? Arch Dermatol Res 
2010; 302: 155-68.
18. Davatchi F, Chams-Davatchi C, Godhsi Z, Shah-
ram F, Nadji A, Hormoz S, et al. Diagnostic value 
of pathergy test in Behçet’s disease according 
to the change of incidence over the time. Clin 
Rheumatol 2011; 30: 1151-55. [CrossRef ]
19. Gyldenløve M, Tvede N, Larsen JL, Jacobsen 
S, Thyssen JP. Low prevalence of positive skin 
pathergy testing in Danish patients with Be-
hçet’s disease. J Eur Acad Dermatol Venereol 
2014; 28: 259-60. [CrossRef ]
20. Ek L, Hedfors E. Behcet’s disease: a review and 
a report of 12 cases from Sweden. Acta Derm 
Venereol 1993; 73: 251-54.
21. Davies PG, Fordham JN, Kirwan JR, Barnes CG, 
Dinning WJ. The pathergy test and Behcet’s 
syndrome in Britain. Ann Rheum Dis 1984; 43: 
70-73. [CrossRef ]
22. Adeeb F, Ugwoke A, Stack AG, Fraser AD. Associ-
ations of HLA-B Alleles with Behçet’s disease in 
Ireland. Clin Exp Rheumatol 2017; 35: 22-23.
23. Leonardo NM, McNeil J. Behcet’s Disease: Is 
There Geographical Variation? A Review Far 
from the Silk Road. Int J Rheumatol 2015; 2015: 
945262.
24. Sazzini M, Garagnani P, Sarno S, De Fanti S, La-
zzano T, Yang Yao D, et al. Tracing Behçet’s dis-
ease origins along the Silk Road: an anthropo-
logical evolutionary genetics perspective. Clin 
Exp Rheumatol 2015; 33: 60-66.
25. Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan 
V, Yazici H. Gastrointestinal involvement in Beh-
cet’s syndrome: a controlled study. Ann Rheum 
Dis 1996; 55: 208-10. [CrossRef ]
26. Lewis KA, Graham EM, Stanford MR. Systematic 
review of ethnic variation in the phenotype of 
Behcet’s disease. Scand J Rheumatol 2007; 36: 
1-6. [CrossRef ]
27. Fitzgerald CW, Adeeb F, Timon CV, Shine NP, Fra-
ser AD, Hughes JP. Significant laryngeal destruc-
tion in a northern European cohort of Behçet’s 
disease patients. Clin Exp Rheumatol 2015; 33: 
123-28.
28. Yazici Y, Shi N, John A. Utilization of biologic 
agents in rheumatoid arthritis in the United 
States: analysis of prescribing patterns in 16,752 
newly diagnosed patients and patients new to 
biologic therapy. Bull NYU Hosp Jt Dis 2008; 66: 
77-85.
29. Soliman MM, Ashcroft DM, Watson KD, Lunt M, 
Symmons DPM, Hyrich KL. Impact of concom-
itant use of DMARDs on the persistence with 
anti-TNF therapies in patients with rheuma-
toid arthritis: results from the British Society for 
Rheumatology Biologics Register. Ann Rheum 
Dis 2011; 70: 583-89. [CrossRef ]
30. Theander E, Husmark T, Alenius GM, Larsson 
PT, Teleman A, Geijer M, et al. Early psoriatic ar-
thritis: short symptom duration, male gender 
and preserved physical functioning at presen-
tation predict favourable outcome at 5-year 
follow-up. Results from the Swedish Early Psori-
atic Arthritis Register (SwePsA) Ann Rheum Dis 
2014; 73: 407-13.
31. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsil-
ambros N, Theodossiadis PG, Papaefthimiou S, 
et al. Infliximab for recurrent, sight-threatening 
ocular inflammation in Adamantiades-Behcet 
disease. Ann Intern Med 2004; 140: 404-406. 
[CrossRef ]
32. Ohno S, Nakamura S, Hori S, Shimakawa M, 
Kawashima H, Mochizuki M, et al. Efficacy, safe-
ty, and pharmacokinetics of multiple admin-
istration of infliximab in Behçet’s disease with 
refractory uveoretinitis. J Rheumatol 2004; 31: 
1362-68.
33. Tugal-Tutkun I, Mudun A, Urgancioglu M, Ka-
mali S, Kasapoglu E, Inanc M, et al. Efficacy of 
infliximab in the treatment of uveitis that is 
resistant to treatment with the combination of 
azathioprine, cyclosporine, and corticosteroids 
in Behçet’s disease: an open-label trial. Arthritis 
Rheum 2005; 52: 2478-84. [CrossRef ]
34. Niccoli L, Nannini C, Benucci M, Chindamo D, 
Cassarà E, Salvarani C, et al. Long-term efficacy 
of infliximab in refractory posterior uveitis of 
Behcet’s disease: a 24-month follow-up study. 
Rheumatology 2007; 46: 1161-64. [CrossRef ]
259
Eur J Rheumatol 2017; 4: 254-9 Adeeb et al. Different anti-TNF agents in Behçet’s disease
